Ocugen to Present at NobleCon16 – Noble Capital Markets’ Sixteenth Annual Investor Conference

Ocugen

MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced it will present at NobleCon16 – Noble Capital Markets’ Sixteenth Annual Investor Conference, to be held February 17-18, 2020 in Hollywood, Florida.

Sanjay Subramanian, Chief Financial Officer of Ocugen, will highlight Ocugen’s ophthalmology pipeline, which includes small molecules, novel biologics and a breakthrough modifier gene therapy platform. Ocugen is currently conducting a Phase 3 clinical trial for OCU300, its small molecule product candidate designed to treat patients with ocular Graft versus Host Disease (oGVHD), with topline results expected in the second half of 2020.

Presentation Details:

Date: Monday, February 17, 2020
Time: 4:30 PM (Eastern Time)
Location: Hard Rock Hotel & Casino, Terrace Ballroom D

READ:  Ocugen Provides Business Update and Full Year 2019 Financial Results

A high-definition video webcast will be accessible for 90 days following the presentation via the following link https://www.ir.ocugen.com.

Source: Ocugen, Inc., 5 Great Valley Parkway, Suite 160, Malvern PA 19355

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee